Lead Product(s) : BX004
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BiomX Gets Orphan Drug Designation for BX004 to Treat Cystic Fibrosis Infection
Details : BX004, developed using the BOLT platform, is in phase 1/2 trials for chronic pulmonary infections caused by Pseudomonas aeruginosa in cystic fibrosis patients.
Product Name : BX004
Product Type : Microorganism
Upfront Cash : Inapplicable
April 01, 2024
Lead Product(s) : BX004
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BX004
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BX004 is a Microorganism solution for nebulizer, which works by targeting Chronic Pseudomonas Aeruginosa Infection in patients suffering from Cystic Fibrosis.
Product Name : BX004
Product Type : Microorganism
Upfront Cash : Inapplicable
November 29, 2023
Lead Product(s) : BX004
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BX004
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : OrbiMed Advisors
Deal Size : $7.5 million
Deal Type : Private Placement
BiomX Announces Second Closing of $7.5 Million Private Placement
Details : BiomX expects to use the aggregate net proceeds to fund clinical development of BX004 for the treatment of lung infections in patients with cystic fibrosis, the development of other programs, and research activities.
Product Name : BX004
Product Type : Microorganism
Upfront Cash : Undisclosed
May 05, 2023
Lead Product(s) : BX004
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : OrbiMed Advisors
Deal Size : $7.5 million
Deal Type : Private Placement
Lead Product(s) : BX004
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BX004, utilizing its proprietary BOLT platform, for the treatment of CF patients with chronic pulmonary infections caused by P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
Product Name : BX004
Product Type : Microorganism
Upfront Cash : Inapplicable
April 10, 2023
Lead Product(s) : BX004
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BX004
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BX004 is active against antibiotic resistant strains of P. aeruginosa and demonstrated great biofilm penetration, an assemblage of surface-associated microbial cells enclosed in an extracellular polymeric substance the major causes for antibiotic resista...
Product Name : BX004
Product Type : Microorganism
Upfront Cash : Inapplicable
February 22, 2023
Lead Product(s) : BX004
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BX004
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : OrbiMed Advisors
Deal Size : $7.5 million
Deal Type : Private Placement
BiomX Announces $7.5 Million Private Placement
Details : BiomX expects to use the net proceeds from the PIPE to fund clinical development of BX004 for the treatment of lung infections in patients with cystic fibrosis, the development of other programs and research activities.
Product Name : BX004
Product Type : Microorganism
Upfront Cash : Undisclosed
February 22, 2023
Lead Product(s) : BX004
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : OrbiMed Advisors
Deal Size : $7.5 million
Deal Type : Private Placement
Lead Product(s) : BX004
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BX004, a novel phage cocktail targeting P. aeruginosa, demonstrated activity against antibiotic resistant strains of P. aeruginosa, as well as enhanced biofilm penetration compared to antibiotic therapies.
Product Name : BX004
Product Type : Microorganism
Upfront Cash : Inapplicable
June 27, 2022
Lead Product(s) : BX004
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BX004
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Cystic Fibrosis Foundation
Deal Size : $5.0 million
Deal Type : Funding
CFF Supporting Phase 1/2 Trial of Phage Therapy for P. aeruginosa Infections
Details : BiomX has been given grant to support a clinical trial of BX004, a phage therapy to fight Pseudomonas aeruginosa infections in people with cystic fibrosis (CF). In lab experiments conducted by BiomX, BX004 killed antibiotic-resistant strains of P. aerugi...
Product Name : BX004
Product Type : Microorganism
Upfront Cash : Undisclosed
May 01, 2022
Lead Product(s) : BX004
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Cystic Fibrosis Foundation
Deal Size : $5.0 million
Deal Type : Funding
Lead Product(s) : rVSV-SARS-CoV-2-S Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : NRx Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IIBR-100 (VSV-ΔG) is a self-propagating live virus vaccine that contains the spike protein of the Wuhan wild-type SARS-CoV-2 virus. Preclinical and phase 1/2 trials have demonstrated no safety signals of concern and have further demonstrated immunologic...
Product Name : IIBR-100
Product Type : Vaccine
Upfront Cash : Inapplicable
September 12, 2021
Lead Product(s) : rVSV-SARS-CoV-2-S Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : NRx Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Company’s IgG product demonstrated a favorable safety profile, and there were no infusion-related reactions or adverse events considered related to study drug.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 31, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable